Welcome to Dwaey, specifically on Ranolazine page.
This medicine contains important and useful components, as it consists of
Ranolazine is available in the market in concentration.
Ranolazine
Before initiating Ranolazine therapy, patients must consult their healthcare provider, especially if they have any underlying medical conditions. Some important precautions include:
- Cardiac Conditions: Ranolazine may cause QT prolongation, which could lead to potentially serious arrhythmias. It should be used cautiously in patients with existing heart conditions, especially those with long QT syndrome or those on medications that can also prolong the QT interval.
- Liver Dysfunction: Ranolazine is metabolized by the liver, so patients with liver impairment may require a dose adjustment. Severe hepatic dysfunction is a contraindication to its use.
- Kidney Disease: Patients with renal impairment (especially severe impairment) may need dose adjustments, as Ranolazine can accumulate in the body due to reduced renal clearance.
- Pregnancy and Lactation: Ranolazine should only be used during pregnancy if absolutely necessary, as there is limited information on its safety. It is also excreted in breast milk, so breastfeeding women should consult their healthcare provider before using it.
- Alcohol Consumption: Alcohol can increase the risk of side effects like dizziness or drowsiness when taken with Ranolazine, so limiting alcohol intake is advisable.
- Other Medications: It is important to inform healthcare providers of all medications being taken, as there are potential drug interactions, particularly with CYP3A inhibitors or inducers.
Ranolazine is primarily prescribed for the management of chronic angina and may be used to improve exercise tolerance and reduce the frequency of angina attacks. It works as a non-nitrate medication for angina management. Key indications include:
- Chronic Stable Angina: Ranolazine is commonly used to treat chronic stable angina, often in combination with other medications like beta-blockers, calcium channel blockers, or nitrates.
- Refractory Angina: It can be used in patients with angina that is refractory to other treatments and helps to reduce the frequency of episodes.
- Heart Disease: It may be used to improve exercise tolerance in patients with coronary artery disease or heart failure (off-label use), though it is not a first-line treatment for these conditions.
- Angina Prevention: Ranolazine is often prescribed to prevent angina attacks when lifestyle changes and other medications have not been fully effective.
Ranolazine is contraindicated in certain conditions to ensure patient safety:
- Severe Liver Impairment: Ranolazine should not be used in patients with severe hepatic dysfunction, as it is metabolized in the liver and can cause harmful accumulation.
- Pre-existing QT Prolongation: The drug is contraindicated in patients with long QT syndrome or those with a prolonged QT interval, as it can further lengthen the QT interval and increase the risk of life-threatening arrhythmias.
- Concurrent Use with Strong CYP3A Inhibitors: Ranolazine should not be used with strong CYP3A inhibitors, such as ketoconazole or itraconazole, because it can increase the concentration of Ranolazine, leading to toxicity.
- Hypersensitivity: Patients with known hypersensitivity to Ranolazine or any of its components should avoid its use.
While Ranolazine is generally well-tolerated, it can cause both common and severe side effects. Patients should be vigilant for any unusual symptoms and consult their healthcare provider if they experience:
Common Side Effects:
- Dizziness or Lightheadedness: Especially when standing up quickly, dizziness is a common side effect of Ranolazine.
- Headache: Some patients report mild to moderate headaches.
- Nausea: Stomach upset or nausea can occur, particularly when starting the medication.
- Constipation: Gastrointestinal issues like constipation are also frequently reported.
- Fatigue: A feeling of tiredness or fatigue may be observed in some individuals.
Serious Side Effects:
- QT Prolongation: Ranolazine can cause QT prolongation, increasing the risk of ventricular arrhythmias like torsades de pointes.
- Severe Dizziness or Syncope: If dizziness becomes severe or if fainting occurs, patients should discontinue the medication and seek medical attention immediately.
- Chest Pain or Palpitations: Some patients may experience unusual heart rhythms or chest discomfort.
- Liver Problems: Elevated liver enzymes may indicate liver dysfunction. Signs include yellowing of the skin or eyes (jaundice) or dark urine.
- Severe Allergic Reactions: Rare but severe allergic reactions, including rash, swelling, and trouble breathing, may require immediate medical intervention.
3
Ranolazine is an anti-anginal and anti-ischemic agent that works by improving blood flow to the heart. Its mechanism of action involves:
- Inhibition of Late Sodium Current: Ranolazine works by inhibiting the late sodium current (INa) in heart muscle cells. This decreases the amount of sodium entering the cells, which reduces calcium overload in the heart muscle.
- Reduction of Myocardial Oxygen Demand: By reducing intracellular calcium levels, Ranolazine helps improve the efficiency of heart muscle contractions and reduces the oxygen demand of the heart.
- Improvement of Blood Flow: It enhances coronary blood flow, helping to alleviate angina and reduce the frequency of chest pain episodes.
- Reduced Ischemia: The drug helps prevent myocardial ischemia, which occurs when the heart muscle is deprived of adequate oxygen supply during periods of increased demand, like physical exertion.
Ranolazine's unique mechanism of action helps manage chronic stable angina by reducing the heart's workload and enhancing oxygen supply to the heart muscle.
Ranolazine interacts with various medications, which may alter its effectiveness or increase the risk of side effects:
- CYP3A Inhibitors: Drugs like ketoconazole, clarithromycin, and ritonavir that strongly inhibit the CYP3A enzyme can significantly increase Ranolazine levels in the blood, leading to toxicity. Dose adjustments are required when using Ranolazine with such medications.
- CYP3A Inducers: Medications like rifampin and phenytoin, which induce the CYP3A enzyme, can reduce the effectiveness of Ranolazine by lowering its levels.
- Digoxin: Ranolazine can increase levels of digoxin, a drug used for heart conditions. Monitoring digoxin levels is recommended when used together.
- Beta-blockers and Calcium Channel Blockers: When used in combination with beta-blockers or calcium channel blockers (like verapamil), Ranolazine can potentiate their effects, leading to excessive bradycardia or low blood pressure.
- Grapefruit Juice: Grapefruit can inhibit CYP3A and should be avoided when using Ranolazine due to the potential for increased drug levels.
The standard adult dose for Ranolazine is:
- Initial Dose: 500 mg twice daily.
- Maintenance Dose: The dose can be increased to 1,000 mg twice daily depending on the patient's response and tolerability.
- Renal or Hepatic Impairment: Dosing adjustments are recommended for patients with impaired liver or kidney function.
Ranolazine is not recommended for use in children under 18 years of age, as its safety and effectiveness have not been established in pediatric populations.
As always, it is critical for patients to consult their healthcare provider before starting Ranolazine to ensure that it is appropriate for their condition and health status.
Patients with renal impairment may require dose adjustments:
- Moderate Renal Impairment (CrCl 30-60 mL/min): Start with 500 mg twice daily, with possible adjustments based on the clinical response and renal function.
- Severe Renal Impairment (CrCl <30 mL/min): Ranolazine should be used with caution in these patients, and dosage adjustments may be necessary, with careful monitoring for side effects.
Not available in a medicine form yet